Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 299 clinical trials
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish  

(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system

  • 268 views
  • 19 Jan, 2021
  • 16 locations
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US  

(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system

  • 1875 views
  • 15 Jan, 2021
  • 15 locations
featured
A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).  

b-cell lymphoma
lymphoma
lymphomas
  • 45 views
  • 14 Dec, 2020
  • 5 locations
featured
A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • 180 views
  • 23 Nov, 2020
  • 1 location
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20

b-cell lymphoma
cancer
diffuse large b-cell lymphoma
hodgkin's disease
r-chop regimen
  • 83 views
  • 08 Nov, 2020
  • 1 location
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy …

b-cell lymphoma
rituximab
chemoimmunotherapy
ct scan
platelet count
  • 8 views
  • 13 Aug, 2020
  • 8 locations
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the administration of tisagenlecleucel in combination with pembrolizumab in patients with r/r DLBCL who have

b-cell lymphoma
anthracyclines
measurable disease
  • 17 views
  • 14 Oct, 2020
  • 8 locations
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.

b-cell lymphoma
measurable disease
rituximab
marginal zone lymphoma
gilbert's syndrome
  • 0 views
  • 22 Mar, 2020
  • 153 locations
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

large B-cell lymphoma (DLBCL).

b-cell lymphoma
chemoimmunotherapy
large cell lymphoma
da-epoch
follicular lymphoma
  • 32 views
  • 08 Mar, 2020
  • 16 locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

  • 0 views
  • 19 Jan, 2021
  • 9 locations